ABSTRACT
Background Although several models exist to predict risk of febrile neutropenia in cancer patients, there is still need to more accurately quantify this risk to minimize morbidity of and mortality from this treatment toxicity.
Material and methods From previous reports of our group, un updated predictive model had emerged. We refined our algorithm even further by using Balanced Bagging Classifier (BBC) machine learning in the previous model derivation cohort, discarding all the missing data. Moreover, we made a web application to make it accessible for experimental clinical use.
Results We used clinical data from 3439 cycles of chemotherapy obtained from the periods of 2010-2011 and 2015-2019, with 133 episodes of febrile neutropenia observed (after 4% of chemotherapy cycles). BBC resulted in a more efficient model as reflected by an area under curve (AUC) of 0.97, accuracy of 0.95, sensitivity of 0.93, and specificity of 0.95. Permutation importance analysis revealed previous febrile neutropenia, cancer type and receipt of previous radiotherapy as the most important features for the BBC model. The web app that integrates the BBC model with a user-friendly user interface has been found to be clinically useful.
Conclusions Using machine learning with our previous data, we are now able to predict the risk of febrile neutropenia more effectively after chemotherapy in cancer patients. The resultant web application is functional and makes use of the developed machine learning model to predict febrile neutropenia.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This study did not receive any funding
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
The local ethical committee of Akdeniz University (for the primary study)
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
Email: drmyildiz{at}yahoo.com.
Funding: No funding has been received for this work.
Data Availability
All data produced in the present study are available upon reasonable request to the authors
